



Xgene's Osteoarthritis Study Accepted as Late-Breaking Abstract to Present at the American College of Rheumatology (ACR) Convergence 2024 Conference

October 29, 2024, Xgene Pharmaceutical Inc., a clinical-stage company developing transformational treatments for various pain conditions with high unmet medical needs, today announced that its Phase 2b osteoarthritis trial has been accepted as a Late-breaking Abstract for presentation at the ACR Convergence 2024 Conference, taking place on November 14–19 at the Walter E. Washington Convention Center in Washington, D.C. The presentation will highlight the findings from the Phase 2b study which evaluated safety and efficacy of XG005 – a dual action conjugate analgesic - in 331 patients with painful osteoarthritis of the knee.

Key findings of the study:

- **Statistically Significant Analgesic Effect:** XG005 demonstrated a significant reduction in pain, which is a crucial outcome for patients suffering from osteoarthritis.
- **Beyond Pain Relief:** Notably, XG005 exhibited benefits beyond pain management. It positively impacted other symptoms associated with osteoarthritis and improved quality of life and sleep quality.

Details for the presentations are as follows:

Poster Number: L08

Submission Number: 1922387

Title: A Phase 2b, Randomized, Double-blind, Placebo-controlled, Dose-ranging and Parallel-group Study to Evaluate the Safety and Efficacy of XG005 in Subjects with Painful Osteoarthritis of the Knee

Session: Poster Session C, (L01–L14) Late-Breaking Posters

Date: Monday November 18, 2024

Presentation Time: 10:30 AM - 12:30 PM

Weblink: <https://acr24.eventscribe.net/SearchByBucket.asp?f=CustomPresfield55&bm=Late-Breaking%20Abstract&pfp=LBA>

“The acceptance of this study as the Late-Breaking Abstract at this prestigious global conference reflects the recognition of the impact of XG005 by world-class key opinion leaders and experts. We are extremely pleased and honored. 52% of patients had at least 50% and/or 70% reduction from Baseline in Daily Walking Pain, and 64.8% patients had such reductions in WOMAC pain sub score. Other efficacy measures also consistently supported each other, showing that XG005 had dose-dependent pain reduction accompanied with improvements in joint stiffness and function along with prompt onset of effect. The compelling effect of XG005 may distinguish it from other currently available therapies and further benefit patients.” said Leon Jiang, Chief Medical Officer at Xgene Pharmaceutical.



About XG005

The company's lead product candidate, XG005, is a dual-MOA non-opioid oral tablet targeting inflammatory and neuropathic pain pathways. It is in active development for acute pain – completed Phase 2/3 in the US in post-surgical clinical model - and for chronic pain with a completed Phase 2 trial in OA and an ongoing cancer pain trial in China. The positive top line results of the OA trial demonstrated analgesic effect and improvement in function [News - Xgene Pharmaceutical Group](#). The company is finalizing the analysis of the data from the completed phase 2/3 acute pain trial and anticipates the top line results to be available by the end of 2024. XG005 has a potential to be highly effective in and safe in chronic pain conditions as well as delaying/eliminating the use of opioids in a post-surgical and an oncology setting.

About Xgene

Xgene Pharmaceutical Inc. is a clinical stage, venture capital-backed, international company utilizing linker technology to create novel, multimodal, conjugated molecules for the treatment of pain and other neurological disorders. Xgene's linker technology is tailored to overcome the challenges of the multimodal therapy approach, and offers potentially better, safer, and more efficient treatments. Current programs are focused on dual-action NCEs with improved analgesic efficacy and tolerability with the pipeline comprising late-stage clinical programs as well as assets in discovery and preclinical development. Xgene has gained recognition and support from leading investment institutions such as Morningside Capital, TF Capital, Ping'an Venture Capital, Hengxu Capital, CITIC Securities and other investment institutions.